The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Open accessAbstract
TP53 is the most commonly mutated gene in human cancer with over 100,000 literature citations in PubMed. This is a heavily studied pathway in cancer biology and oncology with a history that dates back to 1979 when p53 was discovered. The p53 pathway is a complex cellular stress response network with multiple diverse inputs and downstream outputs relevant to its role as a tumor suppressor pathway. While inroads have been made in understanding the biology and signaling in the p53 pathway, the p53 family, transcriptional readouts, and effects of an array of mutants, the pathway remains challenging in the realm of clinical translation. While the role of mutant p53 as a prognostic factor is recognized, the therapeutic modulation of its wild-type or mutant activities remain a work-in-progress. This review covers current knowledge about the biology, signaling mechanisms in the p53 pathway and summarizes advances in therapeutic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 201–236 of 236
Montesinos, P., Beckermann, B. M., Catalani, O., Esteve, J., Gamel, K., Konopleva, M. Y., Martinelli, G., Monnet, A., Papayannidis, C., Park, A., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0044 · Cited by 80
Molecular Basis for Heterogeneity of the Human p53 Protein
Harris, N., Brill, E., Shohat, O., Prokocimer, M., Wolf, D., Arai, N., & Rotter, V (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.12.4650 · Cited by 79
Blanden, A. R., Yu, X., Wolfe, A. J., Gilleran, J. A., Augeri, D. J., O’Dell, R. S., Olson, E. C., Kimball, S. D., Emge, T. J., Movileanu, L., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097550 · Cited by 79
Yee, K. W. L., Martinelli, G., Vey, N., Dickinson, M. J., Seiter, K. P., Assouline, S. E., Drummond, M. W., Yoon, S., Kasner, M. T., Lee, J., et al. (2014) · Blood · doi:10.1182/blood.v124.21.116.116 · Cited by 76
New insights into p53 functions through its target microRNAs
Liao, J.-M., Cao, B., Zhou, X. Y., & Lu, H. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju018 · Cited by 75
A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells
Garufi, A., Trisciuoglio, D., Porru, M., Leonetti, C., Stoppacciaro, A., D’Orazi, V., Avantaggiati, M. L., Crispini, A., Pucci, D., & D’Orazi, G. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-72 · Cited by 75
A Role for the Polyproline Domain of p53 in Its Regulation by Mdm2
Berger, M., Sionov, R. V., Levine, A. J., & Haupt, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008879200 · Cited by 74
Jabbur, J. R., Huang, P., & Zhang, W. (2000) · Oncogene · doi:10.1038/sj.onc.1204017 · Cited by 72
Phosphorylation of p53 by TAF1 Inactivates p53-Dependent Transcription in the DNA Damage Response
Wu, Y., Lin, J., Piluso, L. G., Dhahbi, J. M., Bobadilla, S., Spindler, S. R., & Liu, X. E. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.10.031 · Cited by 72
Identification of a Sequence Element from p53 That Signals for Mdm2-Targeted Degradation
Gu, J., Chen, D., Lichtenstein, J. H. R., Rubin, R. M., & Yuan, Z.-M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1243-1253.2000 · Cited by 71
Patterson, J., Palombella, V. J., Fritz, C., & Normant, E. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0546-0 · Cited by 69
p53’s Extended Reach: The Mutant p53 Secretome
Pavlakis, E., & Stiewe, T. (2020) · Biomolecules · doi:10.3390/biom10020307 · Cited by 68
AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
Sahin, I., Zhang, S., Navaraj, A., Zhou, L., Dizon, D., Safran, H., & El-Deiry, W. S. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0292-1 · Cited by 66
Self-citationThiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53
Yu, X., Blanden, A., Tsang, A. T., Zaman, S., Liu, Y., Gilleran, J., Bencivenga, A. F., Kimball, S. D., Loh, S. N., & Carpizo, D. R. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.107409 · Cited by 64
MicroRNAs, wild-type and mutant p53: More questions than answers
Jones, M. F., & Lal, A. (2012) · RNA Biology · doi:10.4161/rna.20146 · Cited by 60
Prabhu, V. V., Hong, B., Allen, J. E., Zhang, S., Lulla, A. R., Dicker, D. T., & El‐Deiry, W. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-2430 · Cited by 60
Self-citationMutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells
Yoshikawa, K., Hamada, J., Tada, M., Kameyama, T., Nakagawa, K., Suzuki, Y., Ikawa, M., Hassan, N. M. M., Kitagawa, Y., & Moriuchi, T. (2010) · Biomedical Research · doi:10.2220/biomedres.31.401 · Cited by 55
Zerbini, L. F., Wang, Y., Correa, R. G., Cho, J., & Libermann, T. A. (2005) · Cell Cycle · doi:10.4161/cc.4.9.1966 · Cited by 51
Cancer therapeutic targeting using mutant–p53-specific siRNAs
Ubby, I., Krueger, C., Rosato, R., Qian, W., Chang, J., & Sabapathy, K. (2019) · Oncogene · doi:10.1038/s41388-018-0652-y · Cited by 50
Tagawa, M. (2008) · Drug Design Development and Therapy · doi:10.2147/dddt.s3535 · Cited by 49
NUTTHASIRIKUL, N., Limpaiboon, T., Leelayuwat, C., Patrakitkomjorn, S., & Jearanaikoon, P. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1818 · Cited by 48
Mutant and wild-type p53 form complexes with p73 upon phosphorylation by the kinase JNK
Wolf, E. R., McAtarsney, C. P., Bredhold, K. E., Kline, A. M., & Mayo, L. D. (2018) · Science Signaling · doi:10.1126/scisignal.aao4170 · Cited by 47
Facilitated search for specific genomic targets by p53 c-terminal basic DNA binding domain
Liu, Y., Lagowski, J. P., Vanderbeek, G. E., & Kulesz-Martin, M. F. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.11.1189 · Cited by 40
Mouse models dissect the role of p53 in cancer and development
Lozano, G., & Liu, G. (1998) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0096 · Cited by 38
CHIP promotes autophagy‐mediated degradation of aggregating mutant p53 in hypoxic conditions
Maan, M., & Pati, U. (2018) · FEBS Journal · doi:10.1111/febs.14602 · Cited by 37
Sallman, D. A. (2020) · Haematologica · doi:10.3324/haematol.2020.249060 · Cited by 37
Matsumoto, M., Furihata, M., Kurabayashi, A., Sasaguri, S., Araki, K., Hayashi, H., & Ohtsuki, Y. (2004) · Oncology · doi:10.1159/000081001 · Cited by 31
Specific Recognition of p53 Tetramers by Peptides Derived from p53 Interacting Proteins
Gabizon, R., Brandt, T., Sukenik, S., Lahav, N., Lebendiker, M., Shalev, D. E., Veprintsev, D. B., & Friedler, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038060 · Cited by 31
Fine mapping and regulation of the association of p53 with p34cdc2
Wagner, P., Fuchs, A., Götz, C., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201510 · Cited by 31
Warnock, L. J., Knox, A. A., Mee, T. R., Raines, S. A., & Milner, J. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.9.6473 · Cited by 29
Bischof, K., Knappskog, S., Stefansson, I. M., McCormack, E., Trovik, J., Werner, H. M. J., Woie, K., Gjertsen, B. T., & Bjørge, L. (2018) · BMC Cancer · doi:10.1186/s12885-018-4591-3 · Cited by 27
Nakanishi, M., Kaneko, Y. S., Matsushime, H., & Ikeda, K. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1296 · Cited by 20
Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cells
Grespi, F., Landré, V., Molchadsky, A., Daniele, N. D., Marsella, L., Melino, G., & Rotter, V. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.419 · Cited by 18
Ma, G., Shimada, H., Hiroshima, K., Tada, Y., Suzuki, N., & Tagawa, M. (2008) · Dove Medical Press (Taylor and Francis Group) · Cited by 18
Paulmurugan, R., Afjei, R., Sekar, T. V., Babikir, H. A., & Massoud, T. F. (2018) · Oncotarget · doi:10.18632/oncotarget.25138 · Cited by 14
Role of post-translational modifications in regulation of tumor suppressor p53 function
Che, Z., Sun, H., Yao, W., Lü, B., & Han, Q. (2020) · Frontiers of Oral and Maxillofacial Medicine · doi:10.21037/fomm.2019.12.02 · Cited by 8
Cited by
Cell cycle regulation: p53-p21-RB signaling
Engeland, K. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00988-z · Cited by 1,274
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 477
Small molecules targeting protein–protein interactions for cancer therapy
Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71
Metadata
- Authors
- Hernández Borrero, L. J., & El-Deiry, W. S.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 1876
- Issue
- 1
- Pages
- 188556
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W3159454489
- Cited by
- 748
- References
- 236
- FWCI
- 32.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.